Recently new radiopharmaceuticals have been proposed for investigating prostate cancer patients, including metabolic radiotracer such as anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid (18F-FACBC) or probe targeting the prostate-specific membrane antigen (PSMA). These radiotracers showed in literature better performance in the detection of prostate cancer recurrence as compared to choline PET/CT imaging [1, 2].
Titolo: | New radiopharmaceutical markers for metabolism and receptor |
Autore/i: | Ceci, Francesco; Morigi, Joshua James; Zanoni, Lucia; Fanti, Stefano |
Autore/i Unibo: | |
Anno: | 2016 |
Titolo del libro: | Bone Metastases from Prostate Cancer: Biology, Diagnosis and Management |
Pagina iniziale: | 95 |
Pagina finale: | 104 |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1007/978-3-319-42327-2_9 |
Abstract: | Recently new radiopharmaceuticals have been proposed for investigating prostate cancer patients, including metabolic radiotracer such as anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid (18F-FACBC) or probe targeting the prostate-specific membrane antigen (PSMA). These radiotracers showed in literature better performance in the detection of prostate cancer recurrence as compared to choline PET/CT imaging [1, 2]. |
Data stato definitivo: | 5-apr-2018 |
Appare nelle tipologie: | 2.01 Capitolo / saggio in libro |
File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.